Exhibit 99.1 Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency ) 1 Raising Full Year Revenue and Margin Guidance ACTON, Mass. - November 7, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended September 30, 2024. ® "We continue to achieve significant milestones and robust revenue growth," said Jim ...

Insulet’s (PODD) robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD carries a Zacks Rank #2 (Buy) currently.Factors Driving PODD StockInsulet is making significant strides in its key strategic imperatives to help patients manage diabetes efficiently.  The company’s first strategy revolves around increasing access and awareness of Omnipod products. In the second quarter of 2024, ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the BioJet™ Oral Delivery Platform, which is designed to replace injection with needle-free, oral delivery, at the 14th Annual Partnership in Drug Delivery (PODD) meeting in Boston, Massachusetts. "We have now demonstrated the ability to autonomously deliver to the small intestine in canine models with our smaller, 00-size ...

Insulet Corporation (PODD) is driving share gains with its prime Omnipod 5 AID (automated insulin delivery) system, which is highly promising for growth in the upcoming quarters. The company continues to expand the platform to new countries with sensor integrations. A strong solvency position also bodes well for the stock. However, the mounting costs of Omnipod 5 production, coupled with its excessive reliance on this offering, raise concerns for the company.In the past year, this Zacks Rank #2 (Buy) stock ...

SAN FRANCISCO, Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify authentic, respectful, and empowering representations of people living with diabetes. The campaign is from the diaTribe Foundation, a nonprofit dedicated to diabetes education and advocacy, and a leader in the movement to end diabetes stigma. The Spoonful of Laughter campaign is a national initiative using comedy t ...

Insulet Corp.'s (PODD) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product's market potential. The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% ...

UKRAINE - 2021/06/11: In this photo illustration an Insulet Corporation logo is seen on a smartphone ... [+] and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period. The two stocks that focus on the glucose monitoring ...

The company had encouraging news to impart about its leading insulin pump. Specialty device maker Insulet (PODD 0.36%) had some good news to impart to the world early this week, and investors jumped on the stock as a result. As the market started to prepare for its weekend early Friday, Insulet's share price had risen by almost 11% week to date, according to data compiled by S&P Global Market Intelligence. New approval granted Insulet specializes in insulin pumps, and on Monday it formally announced its lat ...

Insulet Corp.'s (PODD) groundbreaking Omnipod 5 Automated Insulin Delivery ("AID") system (Omnipod 5) received the FDA's approval for use by type 2 diabetes patients (ages 18 years and above). The news comes after the company submitted 510(k) for an expanded indication of Omnipod 5 to the FDA, in June 2024, based on the favorable clinical outcomes of the SECURE-T2D pivotal trial. With this development, Omnipod 5 is the first and only AID system indicated for both type 1 and type 2 diabetes. Insulet's Robust ...

Key Takeaways Shares of Insulet and DexCom, which provide devices for patients with diabetes, were the weakestperforming S&P 500 stocks on Tuesday. The losses for the medtech stocks came after Eli Lilly said its blockbuster drug effectively reduced the risk of patients developing type 2 diabetes. Insulet and DexCom have been navigating headwinds related to their user growth outlook. Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled ...